New product: Calquence (acalabrutinib) 100 mg hard capsules

This selective inhibitor of Bruton tyrosine kinase (BTK) is licensed as monotherapy or in combination with obinutuzumab for treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) or as monotherapy for patients who have received ≥ 1prior therapy.

Source:

electronic Medicines compendium